Authors


Kerry LaPlante, PharmD, FCCP, FIDSA, FIDP

Latest:

Antibiotic Stewardship in Outpatient Care

Although there are challenges for clinical and infectious disease pharmacists when trying to apply this concept, here are some considerations and strategies to employ stewardship in this setting.


Jessa Brenon, PharmD, BCPS, BCIDP

Latest:

Long-Acting Lipoglycopeptides for the Treatment of Severe Infections

Long-acting lipoglycopeptides (LGPs) like dalbavancin, oritavancin, and telavancin were developed with extended half-lives, initially targeting acute bacterial skin and skin structure infections (ABSSSIs). However, recent studies have explored their potential in treating other infections, including infective endocarditis (IE), bone and joint infections (BJIs), and bloodstream infections (BSIs), offering an alternative to standard care and outpatient antimicrobial therapy.


Ian Cook, PharmD, BCACP, AAHIVP, DPLA

Latest:

340B Drug Pricing Program: What Is It and Why Is It Important?

The 340B program has had a great impact on access to HIV treatment and prevention services in the US.


Joseph Glowacki, DO

Latest:

Mixed Fungal Brain Abscess

Clinicians review a patient case including diagnosis, treatment, and follow-up.


Jason M. Broderick

Latest:

MRNA COVID-19 Vaccines and Male Fertility

According to a small study, the Moderna and Pfizer COVID-19 vaccines do not impact male fertility.


Grace McComsey, MD, FIDSA

Latest:

Multidisciplinary Perspectives on HIV Treatment

A multidisciplinary panel concludes a discussion on best practices for managing patients with HIV in various healthcare settings and overcoming social health disparities.


Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS

Latest:

COVID-19 Booster Shots and the Future

Key opinion leaders provide some advice for the public regarding COVID-19 booster shots and look to the future of the pandemic.



Jeff Fischer, MBA

Latest:

Longhorn Vaccines Develops Sepsis Vaccine Targeting Key Toxins

This composite peptide vaccine targets key bacterial toxins to prevent sepsis, enhance antibiotic efficacy, reduce inflammation in diseases and cancer, with further data expected soon.


Geraldine A. Finlay, MD

Latest:

Identifying Disparities in Sepsis Diagnosis for Unbiased Care

Risk of inaccuracy with pulse oximeters and clinician knowledge gaps in people of color may affect sepsis evaluations and impact treatment plans.



George Loukatos, MD

Latest:

Future Directions for Managing COVID-19 and Influenza

George Loukatos, MD, shares clinical pearls for the management of the SARS-CoV-2 and influenza viruses.


Subramanya Shyam Ganti, MD, MBBS

Latest:

Challenges in the Management of Mycobacterium abscessus Complex

This pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.



Jennifer Cocohoba, PharmD

Latest:

Contemporary Issues on the Treatment of Women Living with HIV in the US

The increasing presence of multiple non-AIDS comorbidities in women and others living with HIV challenges clinicians to steer away from the approach of optimizing individual chronic conditions but to think more holistically.


Paul Monach, MD, PhD

Latest:

From Pandemic to Endemic

A research agenda focusing on breakthrough infections, reinfections, severity, and sequelae is needed to inform clinical practice when COVID-19 emphasis shifts from eradication to living with the disease.


Karrine D. Brade, PHARMD, BCPS AQ-ID, BCIDP

Latest:

So You Made the Decision to Implement Vancomycin AUC Dosing. Now What?

Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.


Mary Joyce B. Wingler PHARMD, BCIDP

Latest:

The ART of Implementing an Antiretroviral Stewardship Program

By addressing ART-related medication errors and increasing linkage to care, antiretroviral stewardship programs can improve management of inpatients with HIV.


Morgan Petronelli

Latest:

cUTI Roundtable: The Latest Therapeutic Developments

The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.


Monica Verduzco-Gutierrez, MD

Latest:

What We Know But Still Have to Learn About Long COVID

Despite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.


Caitlin Soto, PharmD, BCIDP

Latest:

A Long-Acting Injectable for the Treatment of Candida spp Infections

In the second installment of a 3-part series on long-acting injectables related to various infections, Caitlin Soto, PharmD, BCIDP, provides insights on using rezafungin for invasive candidiasis.



T. Sam Albanesi, MD, MA

Latest:

An Update on Lenacapavir

This new antiretroviral with a unique mechanism of action may be lifesaving for those with treatment-resistant HIV infection.


Jessica Malaty Rivera, MS

Latest:

Communication Breakdown: Dissemination of Public Health Information

Imprecise language can fuel infodemics and misinformation and damage public trust.


Nisha Patel, PharmD, BCPS

Latest:

To Prophylax or not to Prophylax: Preventing CDI

Clinicians look at optimal approaches for trying to avoid Clostridioides difficile infection (CDI).


Jenna Salay, BS

Latest:

What's New In 2024: From the CLSI Subcommittee on Antimicrobial Susceptibility Testing

The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing had its series of meetings to update breakpoints for a variety of classes of antimicrobials.


Alison L. Blackman, PharmD, BCIDP

Latest:

So You Made the Decision to Implement Vancomycin AUC Dosing. Now What?

Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.


Ashley L. O’Leary, PHARMD, AAHIVP

Latest:

Outpatient Antimicrobial Stewardship: The Keys to Developing a Successful Program

This form of stewardship can reduce unnecessary antibiotic prescribing, reduce costs, and optimize patient outcomes.


Brandon Dionne, PharmD, BCPS-AQ ID, BCIDP, AAHIVP

Latest:

Going Viral on Social Media: Integrating Digital Tools into Pharmacy Rotations

In the latest Bench to Bedside column, 2 clinicians discuss the benefits of utilizing social media for learning.


Jesse S. Veisblatt, MD

Latest:

Bad Bugs, New Drugs: A Discussion of Selected New Therapeutics From IDWeek 2022

Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.

© 2024 MJH Life Sciences

All rights reserved.